Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Commentary|Articles|April 7, 2026
Gynecologic Oncologists Preview the Abstracts Set to Drive Conversation at SGO 2026
Author(s)Caroline Seymour
Fact checked by: Kyle Doherty
Read below to hear from Drs Markman and Slomovitz on the sessions and abstracts they’re looking forward to at this year’s SGO Annual Meeting on Women’s Cancer.
Advertisement
Advertisement
Ahead of this year’s
Related to this article
The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.
The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Advertisement
Advertisement